BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,422,196 shares of the biotechnology company’s stock after selling 68,180 shares during the quarter. Segall Bryant & Hamill LLC owned 0.69% of BioCryst Pharmaceuticals worth $10,695,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Prudential Financial Inc. raised its stake in shares of BioCryst Pharmaceuticals by 10.2% during the fourth quarter. Prudential Financial Inc. now owns 983,033 shares of the biotechnology company’s stock valued at $7,392,000 after purchasing an additional 90,603 shares during the period. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after buying an additional 1,583,826 shares during the period. Fox Run Management L.L.C. lifted its holdings in BioCryst Pharmaceuticals by 67.4% in the 4th quarter. Fox Run Management L.L.C. now owns 68,040 shares of the biotechnology company’s stock worth $512,000 after buying an additional 27,406 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $299,000. Finally, Hillsdale Investment Management Inc. grew its stake in shares of BioCryst Pharmaceuticals by 65,213.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after acquiring an additional 541,270 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on BCRX. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Down 3.3 %

BCRX stock opened at $7.80 on Thursday. The firm’s 50-day simple moving average is $8.15 and its 200 day simple moving average is $7.82. The stock has a market cap of $1.63 billion, a PE ratio of -12.79 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the company posted $0.28 EPS. The company’s revenue for the quarter was up 40.8% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.